NCT03793686终止1 期
A Phase 1 Double Blind, Randomized Clinical Study to Evaluate the Safety of Human Milk Oligosaccharides Following Antibiotic Therapy in Subjects With C. Difficile-associated Diarrhea
Prolacta Bioscience1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2018年12月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Characterization of Adverse Events in a dose escalation study of PBCLN-003
研究概览
简要总结
This Phase I double blind, randomized clinical study to evaluate the safety of human milk oligosaccharides (HMO) is designed to assess the safety and dosage ranging of PBCLN-003 in adults with Clostridium difficile-associated diarrhea (CDAD). Within 3 dose cohort, subjects will be randomized in a 3:1 ratio to receive PBCLN-003 or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Enrollment episode of CDAD diagnosed based on > 3 loose stools per day and detection of CD toxin by nucleic acid amplification tests (NAAT), EIA or GDH
- •Mild to moderate CDAD during enrollment episode (per Society of Hospital Epidemiologists of America (SHEA)/lnfectious Disease Society of America(ISDA) criteria)
- •Current therapy with standard of care antibiotics for recurrent CDAD(vancomycin, metronidazole, fidaxomicin)
- •BMI > 18.5 and < 40
- •Age 18 years or older
- •Agreement to adhere to the study protocol
- •Informed consent is obtained
- •Women who are capable of bearing children must have a negative pregnancy test at the time of screening
- •Female subjects of childbearing potential must use birth control (defined as oral or injectable contraceptives, intrauterine devices, surgical sterilization or a combination of a condom and spermicide) during the study period and for up to 8 weeks after the first drug of study.
排除标准
- •Severe CDAD during enrollment episode (per SHEA/ISDA criteria) characterized as follows:
- •History of five (5) or more recurrences of CDAD within the past 12 months prior to potential study enrollment
- •History of fecal microbiome transplant or other microbiome directed experimental intervention for CDAD
- •History (ever) of CD complicating inflammatory bowel disease (Crohn's disease, ulcerative colitis), or history of bowel resection surgery (other than uncomplicated appendectomy) or history of other infectious diarrhea or diarrhea of unknown etiology since the initial episode of CDAD
- •Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
- •Initiating a new diet or weight loss amounting to 10% within two weeks prior to date of study entry
- •Enrolled in another clinical study for the therapy of CDAD or affecting nutritional management during the study period
- •Enrolled or has been enrolled in another experimental (IND) study within two weeks prior to date of study entry
- •Is pregnant or lactating
- •History of swallowing difficulties, including dysphagia or odynophagia for liquids or solids
- •Use of any Probiotics (any formulation) within the two weeks prior to date of study entry
- •New, or a change in the consumption of the following prescription medications or over-the-counter (OTC) medications within two weeks prior to date of study entry:
- •Proton pump inhibitors (for example: Prilosec®, Nexium®)
- •Histamine-2 receptor antagonists (for example: Zantac®, Pepcid®)
- •Consumption of the following prescription medications during the current enrollment episode: • Bezlotuxamab/Zinplava®
研究组 & 干预措施
Experimental
Experimental
PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
干预措施: PBCLN-003 (Drug)
Placebo
Placebo Comparator
Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
干预措施: Placebo (Drug)
结局指标
主要结局
Characterization of Adverse Events in a dose escalation study of PBCLN-003
时间窗: Up to 8 Weeks
Comparison of adverse event reporting and grading results between groups using physical exams, safety related blood tests, and urinalysis, adverse event reports, and subject complaint logs.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety Study of Human Milk Oligosaccharides in Healthy AdultsHealthyNCT05516225Prolacta Bioscience32
Unknown
1 期
A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected PatientsChronic Hepatitis CNCT02617615Microbio Co Ltd40
撤回
1 期
The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult SubjectsHealthyNCT05607589Daewoong Pharmaceutical Co. LTD.72
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy SubjectsHealthy VolunteersNCT04497662Kiniksa Pharmaceuticals, Ltd.52
进行中（未招募）
1 期
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male ParticipantsHealthy ParticipantsNCT06517914Yuhan Corporation94